Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

Fig. 4

METTL3 drives CRC tumorigenesis and metastasis in vivo. a-b, Subcutaneous tumor models in nude mice showing the tumor growth rate (left) and tumor weights (right) at day 28 after the implantation of METTL3-knockdown and control SW620 and HCT116 cells (n = 5 mice per group). c, Representative H&E staining (scale bar: 100 μm) and quantification of metastatic lung nodules at day 60 after the tail vein injection of METTL3- knockdown or control SW620 cells (n = 5 mice per group). Arrow: metastatic lung nodules. Five sections were evaluated for each lung. d, In vivo limiting dilution assay showing the estimated frequency of CSCs among METTL3-knockdown and control SW620 cells with or without SOX2 overexpression. Response: mice developed subcutaneous tumor (n = 5 mice per group). e-f, Tumor growth rate and tumor weights in two PDX models of intratumoral treatment with siMETTL3 and siNC. g-h, Representative images and quantification of H&E and immunostaining (scale bar: 100 μm) of METTL3, SOX2, and EpCAM in two PDX-based subcutaneous tumor models. All data and error bars are presented as the mean ± SDs. *P < 0.05, **P < 0.01 (Student’s t-test)

Back to article page